Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100005XF5
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 129.47 m CNY | 123.39 m CNY |
| Gross profit | 43.93 m CNY | 40.99 m CNY |
| Operating income | -231.64 m CNY | -241.02 m CNY |
| EBIT | -191.03 m CNY | -258.94 m CNY |
| Net income | -201.38 m CNY | -268.05 m CNY |
| Diluted EPS – continuing operations | -0.54 CNY | -0.72 CNY |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
More stocks
- Koppers Holdings Inc. (KOP)
- Sino-High (China) Co. Ltd. (301076.SZ)
- Shenzhen Sunnypol Optoelectronics Co Ltd (002876.SZ)
- Jiangxi Sanxin Medtec Co Ltd (300453.SZ)
- LSB INDUSTRIES, INC. (LXU)
- Jintuo Technology Co Ltd (603211.SS)
- Viridien SA (VIRI.PA)
- V V Food & Beverage Co Ltd (600300.SS)
- Suzhou Keda Technology Co Ltd (603660.SS)
- Imperial Metals Corporation (III.TO)
- SHORE BANCSHARES INC (SHBI)
- PT Soho Global Health Tbk (SOHO.JK)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.